AMRX Amneal Pharmaceuticals, Inc.
Q3 2025 10-Q
Amneal Pharmaceuticals, Inc. (AMRX) 10-Q quarterly report for Q3 2025, filed with SEC EDGAR on Nov 6, 2025 for the fiscal period ending Sep 30, 2025. This page provides AI-powered analysis including management discussion & analysis (MD&A), risk factor updates, and key quarterly financial data such as revenue and net income extracted from XBRL.
AI Filing AnalysisQ3 2025 10-Q
Management Discussion & Analysis
- • No quarterly revenue or YoY change disclosed in MD&A text
- • No profitability or margin figures provided in MD&A section
Risk Factors
- • New tax distribution risk due to increased cash distributions to AvKARE Sellers: $38.8M in nine months ended 9/30/25 vs $14.4M prior year
- • Material debt refinancing changes reducing financing cash outflows by $129.2M to $21.4M nine months ended 9/30/25
Quarterly Financial SummaryXBRL
Revenue
$785M
Net Income
$2M
Gross Margin
34.9%
Operating Margin
9.0%
Net Margin
0.3%
ROE
-2.2%
Total Assets
$3.6B
Source: XBRL data from Amneal Pharmaceuticals, Inc. Q3 2025 10-Q filing on SEC EDGAR. All figures in USD.
Get deeper insights on Amneal Pharmaceuticals, Inc.
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.